Chi-Med planning Hong Kong listing

Hutchison China MediTech Ltd. (LSE:HCM; NASDAQ:HCM) announced its intent to list on the Hong Kong stock exchange via a global offering. The company has submitted an application seeking a listing in 3Q19; terms have yet to be announced.

In November 2018, Chi-Med launched Elunate fruquintinib in China to treat colorectal cancer. Within two years, it hopes to gain approval of two other cancer therapies: c-Met inhibitor savolitinib to treat non-small cell lung cancer (NSCLC) and surufatinib (formerly sulfatinib), a selective inhibitor of VEGF receptor, FGFR and CSF1R, to treat pancreatic neuroendocrine tumors...